Tildrakizumab (Ilumetri, Almirall) Shows Sustained Improvements in Skin and Quality of Life in PsO Patients; Study Uses WHO 5 Well-Being Index as Primary Endpoint

September 18, 2025

WHO Adds Biologics for Psoriasis and Sunscreen for Albinism to Essential Medicines List

September 15, 2025

First Off: Johnson & Johnson Submits Application to EMA for Oral Icotrokinra in Psoriasis

September 11, 2025

Arcutis Submits sNDA for Roflumilast Cream 0.3% (Zoryve) for Psoriasis in Children Down to Age 2

September 3, 2025

NPF Hosts Its First-ever Total Body Wellness Day: Find Out What to Expect

August 26, 2025

Raising Awareness About Generalized Pustular Psoriasis

August 12, 2025

Eight Pro Tips to Help Patients With Skin Diseases Look Their Best

August 7, 2025

What Is Broc Shot? Get to Know the First Supplement to Ever Receive the NPF’s Seal of Recognition

August 1, 2025

J&J Asks FDA to Add PsA Joint Damage Inhibition Data to Guselkumab (Tremfya) Label

July 30, 2025

Immune Drift: A Guide to Understanding Mechanisms by Biologic Class

July 29, 2025

Johnson & Johnson Submits NDA for Oral Icotrokinra in Plaque Psoriasis

July 22, 2025

U.S. FDA Accepts Supplemental New Drug Application for Deucravacitinib (Sotyktu, Bristol Myers Squibb) in PsA

July 21, 2025